黄芩苷治疗非酒精性脂肪性肝炎大鼠抗炎的疗效

doi:10.6040/j.issn.1671-7554.0.2019.475

摘要/Abstract

摘要： 目的观察黄芩苷对非酒精性脂肪性肝炎(NASH)的治疗效果及其抗炎疗效。方法采用高脂饮食诱导建立大鼠NASH模型,给予不同剂量的黄芩苷(15 、30、60 mg/kg·d)治疗后,测定大鼠肝质量及体质量变化,苏木精-伊红(HE)染色观察肝组织病理学变化,并测定血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)水平,比色法测定肝组织超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)酶活性及丙二醛(MDA)含量变化,酶联免疫吸附(ELASA)测定肝组织肿瘤坏死因子α(TNFα)、白介素-6(IL-6)、白介素-1β(IL-1β)含量变化。结果经黄芩苷治疗后,NASH大鼠的体质量及肝质量减轻(F=1609.79, P<0.001;F=155.17, P<0.001),二指标随剂量增加而下降。经不同剂量黄芩苷治疗后,病理学可见肝细胞脂肪变性逐渐减轻,小叶间炎性细胞浸润逐渐减少。治疗后,血清ALT和AST减少(F=177.16,P<0.001;F=2 998.11,P<0.001),随剂量增加而减少。而肝脏GSH、SOD酶活性经黄芩苷治疗后增加(F=398.47,P<0.001;F=256.07,P<0.001),随治疗浓度增加而增加。肝组织MDA的变化则相反(F=237.98,P<0.001),随治疗浓度增加而下降。肝组织TNFα、IL-1β、IL-6含量经黄芩苷治疗后均降低(F=399.15,P<0.001;F=314.76,P<0.001;F=108.38,P<0.001),三者随治疗浓度增加而下降。结论黄芩苷能减轻NASH大鼠的脂肪变性程度,通过增加GSH、SOD酶的活性,减少TNFα、IL-1β、IL-6炎性因子的产生,缓解肝脏的炎症,发挥其抗炎作用。

关键词: 黄芩苷, 抗炎, 非酒精性脂肪性肝炎, 肿瘤坏死因子α, 白介素

Abstract: Objective To investigate the efficacy of baicalin in the treatment of non-alcoholic steatohepatitis(NASH)in rat models and the anti-inflammatory effect. Methods After NASH rat models were induced, they were intragastrically given different doses of baicalin 15, 30, 60 mg/(kg·d). The body weight and liver weight were measured. The histopathology changes in hepatic steatosis were observed with hematoxylin-eosin(HE)staining. The serum alanine amiotransferase(ALT)and aspartate aminotransferase(AST)levels were assessed. The changes of hepatic reduced glutathione hormone(GSH), superoxide dismutase(SOD)and hepatic malondialdehyde(MDA)were detected with spectrophotometry. The levels of tumor necrosis factor α(TNFα), interleukin 6(IL-6)and interleukin 1β(IL-1β)in liver tissues were measured with enzyme linked immunosorbent assay(ELASA). Results After baicalin treatment, the body weight and liver weight of NASH rats were significantly reduced(F=1 609.79, P<0.001; F=155.17, P<0.001) 山东大学学报 (医学版)57卷7期 -艾正琳,等.黄芩苷治疗非酒精性脂肪性肝炎大鼠抗炎的疗效 \=-in a dose-dependent manner. The steatosis of hepatic cells gradually decreased, and the infiltration of inflammatory cells was relieved. The serum ALT and AST reduced(F=177.16, P<0.001; F=2 998.11, P<0.001), the activity of GSH and SOD increased(F=398.47, P<0.001; F=256.07, P<0.001); the MDA;TNFα, IL-1β and IL-6 levels decreased(F=237.98, P<0.001;F=399.15, P<0.001; F=314.76, P<0.001; F=108.38, P<0.001), in a dose-dependent manner. Conclusion Baicalin can alleviate the degree of steatosis and inflammation in NASH rats. By increasing the activity of GSH and SOD enzymes, and reducing the levels of TNFα, IL-1β and IL-6, it exerts anti-inflammatory effects and alleviates liver inflammation.

Key words: Baicalin, Anti-inflammation, Nonalcoholic steatohepatitis, Tumor necrosis factor α, Interleukin

中图分类号:

R575.1

艾正琳,洪珊,胡居龙,李坪,周玉玲,梁秀霞,姚树坤. 黄芩苷治疗非酒精性脂肪性肝炎大鼠抗炎的疗效[J]. 山东大学学报 (医学版), 2019, 57(7): 55-60.

AI Zhenglin, HONG Shan, HU Julong, LI Ping, ZHOU Yuling, LIANG Xiuxia, YAO Shukun. Anti-inflammation effect of baicalin on rat models of nonalcoholic steatohepatitis[J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 55-60.

参考文献

[1] Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives [J]. J Gastroenterol, 2017, 52(2): 164-174.
[2] Xu ZJ, Shi JP, Yu DR, et al. Evaluating the relationship between metabolic syndrome and liver biopsy-proven non-alcoholic steatohepatitis in China: a multicenter cross-sectional study design [J]. Adv Ther, 2016, 33(11): 2069-2081.
[3] Younossi ZM, Korenning AB, Adelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology, 2016, 64(1): 73-84.
[4] Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials [J]. Hepatology, 2019, 16. doi: 10.1002/hep.30664.
[5] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia [J]. J Hepatol, 2017, 67(4): 862-873.
[6] Polyzos SA, Kountouras J, Mantaoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics [J]. Metabolism, 2019, 92: 82-97. doi: 10.1016/j.metabol.2018.11.014.
[7] Yang J, Fernández-Galilea M, Martínez-Fernández L, et al. Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation [J]. Nutrients, 2019,18,11(4): 872. doi: 10.3390/nu11040872.
[8] Chirumbolo S. Baicalin in flavocoxid may act against hepatitis B virus via a pro-inflammatory pathway [J]. Inflamm Res, 2018, 67(3): 203-205.
[9] Zhang J, Zhang H, Deng X, et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice [J]. Life Sci, 2018, 192: 46-54. doi: 10.1016/j.lfs.2017.11.027.
[10] He P, Wu Y, Shun J, et al. Baicalin ameliorates liver injury induced by chronic plus binge ethanol feeding by modulating oxidative stress and inflammation via CYP2E1 and NRF2 in mice [J]. Oxid Med Cell Longev, 2017, 2017:4820414. doi: 10.1155/2017/4820414.
[11] 艾正琳, 张伟硕, 姚树坤, 等. 黄芩苷对体外氧化应激模型中肝型脂肪酸结合蛋白表达的影响及意义[J]. 中华肝脏病杂志, 2011, 19(12): 53-57. AI Zhenglin, ZHANG Weishuo, YAO Shunkun, et al. Effect of baicalin on liver fatty acid binding protein in oxidative stress in vitro[J]. Chinese Jounal of Hepatology, 2011, 19(12): 53-57.
[12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3): 163-166. The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Liver Disease Association. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition [J]. Chinese Jounal of Hepatology, 2010, 18(3): 163-166.
[13] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病诊疗指南(2018更新版)[J]. 中华肝脏病杂志, 2018, 26(3): 195-203.
[14] Lieber CS, Leo MA, Mak KM, et al. Model of nonalcoholic steatohepatitis [J]. Am J Clin Nutr, 2004, 79(3): 502-509.
[15] Sunaram V, Morgan TR. Will studies in nonalcoholic steatohepatitis help manage alcoholic steatohepatitis? [J]. Clin Liver Dis, 2019, 23(1): 157-165.
[16] Farzanegi P, Dana A, Ebrahimpoor Z, et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease(NAFLD): Roles of oxidative stress and inflammation [J]. Eur J Sport Sci, 2019, 19(7): 994-1003.
[17] Chen K, Ma J, Jia X, et al. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans [J]. Biochim Biophys Acta Rev Cancer, 2019, 1871(1): 117-125.
[18] Liang Q, Chen H, Xu X, et al. miR-182-5p Attenuates high-fat -diet-induced nonalcoholic steatohepatitis in mice [J]. Ann Hepatol. 2019, 18(1): 116-125.
[19] Jia R, Du J, Cao L,et al. Antioxidative, inflammatory and immune responses in hydrogen peroxide-induced liver injury of tilapia(GIFT, Oreochromis niloticus)[J]. Fish Shellfish Immunol, 2018, 31(84): 894-905.
[20] Uchio R, Murosaki S, Ichikawa H. Hot water extract of turmeric(Curcuma longa)prevents non-alcoholic steatohepatitis in mice by inhibiting hepatic oxidative stress and inflammation [J]. J Nutr Sci, 2018, 27(7): 36. doi: 10.1017/jns.2018.27. eCollection 2018.
[21] Sutti S, Jindal A, Locatelli I, et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH [J]. Hepatology, 2014, 59(3): 886-897.
[22] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression [J]. Cell Mol Life Sci, 2019, 76(1): 99-128.
[23] Chen Z, Yu R, Xiong Y, et al. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease [J]. Lipids Health Dis, 2017, 16(1): 203. doi: 10.1186/s12944-017-0572-9.
[24] Henkel J, Coleman CD, Schraplau A, et al. Augmented liver inflammation in a microsomal prostaglandin E synthase 1(mPGES-1)-deficient diet-induced mouse NASH model [J]. Sci Rep, 2018, 8(1): 16127.
[25] Atay K, Canbakan B, Koroglu E, et al. Apoptosis and disease severity is associated with insulin resistance in non-alcoholic fatty liver disease [J]. Acta Gastroenterol Belg, 2017, 80(2): 271-277.
[26] Jorge ASB, Andrade JMO, Paraiso AF, et al. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity [J]. Obes Res Clin Pract, 2018, 12(Suppl 2): 1-8.
[27] Nawaz R, Zahid S, Idrees M, et al. HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-γ operative, leading liver en-route to non-alcoholic steatohepatitis [J]. Inflamm Res, 2017, 66(6): 477-486.
[28] Lambertucci F, Arboatti A, Sedlmier MG, et al. Disruption of tumor necrosis factor alpha receptor 1 signaling accelerates NAFLD progression in mice upon a high-fat diet [J]. J Nutr Biochem, 2018, 58: 17-27. doi: 10.1016/j.jnutbio.2018.04.013.
[29] Nelson JE, Handa P, Aouizerat B, et al. Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms [J]. Aliment Pharmacol Ther, 2016, 44(11-12): 1253-1264.

相关文章 15

[1]	李鸿皓,于晶,陈亚丽,郭守刚. 20例NMOSD患者CD4⁺CD25⁺FoxP3⁺调节性T细胞数量和FoxP3 mRNA的表达水平[J]. 山东大学学报 (医学版), 2022, 60(4): 50-54.
[2]	陈虹瑜,曲竹丽,孙琪,赵华强,马川. IL-1β介导的ERK通路对大鼠髁突软骨细胞外基质的作用[J]. 山东大学学报 (医学版), 2019, 57(5): 80-86.
[3]	陈欧,李国勇,刘爱红,朱晓波,陈少杰,王一彪. 网络药理学预测麻黄治疗哮喘的抗炎作用机制[J]. 山东大学学报 (医学版), 2019, 57(1): 55-61.
[4]	李竹青,张文雪,李理想,王鹏,于岩波,左秀丽,李延青. 丁酸钠下调IRAK1改善肠易激综合征内脏高敏感[J]. 山东大学学报 (医学版), 2018, 56(9): 23-28.
[5]	王波,薛江,刘爱虹,翟蕊蕊,王一彪. 雷帕霉素调控巨噬细胞表型改善肺动脉高压[J]. 山东大学学报 (医学版), 2018, 56(4): 51-57.
[6]	姬原原,包景泊,赵旭,曹鲁宁,崔敏,张娜,于灵芝. 白介素17F促进大鼠成骨细胞增殖、矿化和Runx2、Osterix的表达[J]. 山东大学学报（医学版）, 2017, 55(8): 24-29.
[7]	张鹏亮,张龙腾,李爱玲,沈涛,娄红祥,王小宁. 植物内生真菌Leptosphaeria sp.中两个新氧杂蒽酮类化合物leptosphaerins H和I的分离及抗炎活性[J]. 山东大学学报（医学版）, 2017, 55(11): 27-31.
[8]	孙鹏飞,孟晓,张凯,黎莉. 抵抗素样分子 β在动脉粥样硬化斑块稳定性中的作用[J]. 山东大学学报（医学版）, 2016, 54(3): 1-4.
[9]	穆军,单丽娜,翟英杰,翟光喜. 黄芩苷类脂纳米囊制剂的制备及大鼠口服药物动力学[J]. 山东大学学报（医学版）, 2016, 54(1): 22-28.
[10]	于昕, 刘晓静, 刘向群. 黄芩苷抑制ox-LDL诱导内皮细胞凋亡的作用[J]. 山东大学学报（医学版）, 2015, 53(5): 5-9.
[11]	仇会会1，叶丽平1，温有锋2，李丹1，宋佳1. IL-6对卵巢癌细胞bcl-2、cyclinD1和VEGF表达的影响[J]. 山东大学学报（医学版）, 2014, 52(6): 17-21.
[12]	韩文洁1,于苏国1，崔翔宇2. N-乙酰半胱氨酸对胰岛素抵抗大鼠GLP-1、IL-6表达的影响[J]. 山东大学学报（医学版）, 2014, 52(6): 12-16.
[13]	潘家超1,2，张乐1,2，徐琳琳3，单晓宇2，杜文军2，陈士俊2. 黑素瘤缺乏因子2诱导的固有免疫在慢性乙型肝炎发病机制中的作用[J]. 山东大学学报（医学版）, 2014, 52(4): 74-79.
[14]	尹海鹏，刘向群，于昕，王敏. 黄芩苷对ApoE-/-小鼠动脉粥样硬化及VE-钙黏蛋白表达水平的影响[J]. 山东大学学报(医学版), 2013, 51(9): 26-30.
[15]	高淑春，耿大影，崔蕾，张立新，张琴冈，陈士俊. 替比夫定对慢性乙型肝炎血清IL-2和IL-6的影响[J]. 山东大学学报(医学版), 2012, 50(8): 92-95.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed